New combo therapy aims to shrink tumors before surgery in stomach cancer
NCT ID NCT07257575
Summary
This study is testing whether adding a new immunotherapy drug called serplulimab to standard chemotherapy (FLOT) works better for people with stage III stomach cancer. The goal is to see if the combination helps more patients achieve a 'pathological complete response,' meaning no detectable cancer cells are found in tissue removed during surgery. Researchers will compare the combination to chemotherapy alone in 138 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
No. 106, Zhongshan 2nd Road, Yuexiu District
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.